(DRAFT)
FOOD AND DRUG ADMINISTRATION
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES
ADVISORY
COMMITTEE
Hilton Hotel
8727 Colesville Road
Silver Spring, MD 20910
DRAFT AGENDA (revised 10/4/04)
8:00 a.m. Administrative Remarks,
William Freas, PhD, Executive Secretary
8:10 a.m. Opening Remarks
Suzette Priola, PhD, Acting Chairperson
Introduction
Dr. Jesse Goodman, Director,
Center for Biologics Evaluation and Research, FDA
Presentation of Plaques to Retiring Committee Members
Dr. Jesse Goodman
8:25 a.m. Informational Presentation #1: USDA BSE Licensed Tests and Enhanced Surveillance Program (15 minutes), Lawrence Elsken, DVM, USDA (confirmed)
Informational Presentation #2: USDA Review of Worldwide BSE Situation and USDA Responses (15 minutes), Lisa Ferguson, DVM, USDA (confirmed)
Informational Presentation #3: New CFSAN BSE-Food Safety Rules (15 minutes), Rebecca Buckner,
Ph.D., CFSAN/FDA
Informational Presentation # 4: Update on Animal Feed Rulemaking (15 minutes), Burt Pritchett, DVM, CVM
9:25 a.m. Questions for Presenters
9:35 a.m. OPEN PUBLIC HEARING (30 minutes)
10:05 Informational Presentation #5: Labeling Claims for TSE Clearance Studies for Plasma Derivative Products (20 minutes),
Dorothy Scott, MD, OBRR, FDA (confirmed)
10:25 BREAK
10:45 a.m. Topic – Presumptive Transfusion Transmissions of Variant CJD (vCJD): Consideration of Current FDA-Recommended Safeguards
A. FDA Introduction (15 minutes), David Asher, MD, OBRR/FDA (confirmed)
B. Presumptive Transfusion Transmission of vCJD (review of CJD and vCJD: UK and EU epidemiology, case reports, surveillance and projections, potential public health implications, and responses) (45 minutes), Professor Robert G. Will, MD, UK CJD Surveillance Unit (confirmed).
C. Comparison of the Transfusion Risk for CJD vs. vCJD (10 minutes), Steven Anderson, PhD, OBE/FDA (confirmed)
D. Leukoreduction and Its Failure to Remove Most Infectivity from Blood (15 minutes), Robert G. Rohwer, PhD (confirmed)
12:10 p.m. Questions for Speakers
12:25 LUNCH
1:25
E. Changes in Canadian CJD/vCJD Blood Safety Policies (not confirmed) (20 min), Dr. Peter Ganz, HealthCanada
F. Current Safeguards for Blood Products Recommended by FDA (15 minutes), Dorothy Scott, MD, OBRR/CBER (confirmed)
G. Possible Effects of Prior CJD-Related Blood Donor Deferrals on Blood Supply (30 minutes), Alan Williams, PhD, OBRR/CBER (confirmed)
2:30 Questions for Speakers
2:45 OPEN PUBLIC HEARING
3:15 BREAK
3:35 Question to the Committee
3:45 Committee Discussion and Vote
5:00 ADJOURN